10,7859,09042,41933,170FazaClo LD (1)
4,118-22,023-FazaClo HD (1)
$ 181,942$ 80,935$ 580,527$ 266,518 (1) Net sales for the year ended December 31, 2012 reported by Jazz Pharmaceuticals plc include net sales from the historic Azur Pharma business for the period beginning January 18, 2012 and net sales from the historic EUSA Pharma business beginning June 12, 2012.
The following unaudited pro forma information represents the combined net product sales for the three months and years ended December 31, 2012 and 2011, respectively, as if the merger with Azur Pharma, the acquisition of EUSA Pharma and the disposition of the women's health business had each been completed on January 1, 2011: SUMMARY OF PRODUCT SALES, NET (PRO FORMA) (In thousands) (Unaudited) Three Months EndedYear EndedDecember 31,December 31,2012201120122011Xyrem
$ 113,514$ 71,845$ 378,663$ 233,348Erwinaze/Erwinase
10,16512,68848,87352,622Total pro forma net sales
$ 181,942$ 129,163$ 662,957$ 422,746 JAZZ PHARMACEUTICALS PLCCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands) (Unaudited) December 31,December 31,20122011ASSETSCurrent assets:Cash and cash equivalents
7,4451,690Deferred tax assets, net
35,813-Other current assets
19,1131,260Total current assets
551,572199,131Property and equipment, net
7,2811,557Intangible assets, net
|SOURCE Jazz Pharmaceuticals plc|
Copyright©2012 PR Newswire.
All rights reserved